Amaç: The aim of our study was to evaluate prognostic factors influencing overall (OS) and disease-free survival (DFS) in a population of patients affected by peritoneal metastazis ( PM ) with surgery plus HIPEC.

Gereç-Yöntem: From June 2020 to April 2022, Twenty-eight patients who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at our center were analyzed from retrospective analysis of a prospectively collected database.

Bulgular: Peritoneal metastasis from colorectal cancer was the leading indication. The median PCI was 14,5 (range, 4–36). Regarding the completeness of cytoreduction (CC), a score of 0 and 1 was achieved in 68%. Median overall survival rates for patients for colon cancer, ovarian cancer and gastric cancer were 54, 48 and 17 months respectively. The occurrence of grade-III and -IV complications was seen % 53,6. No 30-day mortality occurred.

Sonuç: Experienced centers are able to provide low-morbidity cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without mortality. Strict patient selection during the time period significantly improved CC scores.